These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 21417735)

  • 1. Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates.
    Stephan JP; Kozak KR; Wong WL
    Bioanalysis; 2011 Mar; 3(6):677-700. PubMed ID: 21417735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper.
    Gorovits B; Alley SC; Bilic S; Booth B; Kaur S; Oldfield P; Purushothama S; Rao C; Shord S; Siguenza P
    Bioanalysis; 2013 May; 5(9):997-1006. PubMed ID: 23641692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugates.
    Hoofring SA; Lopez R; Hock MB; Kaliyaperumal A; Patel SK; Swanson SJ; Chirmule N; Starcevic M
    Bioanalysis; 2013 May; 5(9):1041-55. PubMed ID: 23641695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analytical and bioanalytical technologies for characterizing antibody-drug conjugates.
    Alley SC; Anderson KE
    Curr Opin Chem Biol; 2013 Jun; 17(3):406-11. PubMed ID: 23570980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioanalytical approaches for characterizing catabolism of antibody-drug conjugates.
    Saad OM; Shen BQ; Xu K; Khojasteh SC; Girish S; Kaur S
    Bioanalysis; 2015; 7(13):1583-604. PubMed ID: 26226309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing specificity for immunogenicity assays.
    Swanson SJ; Chirmule N
    Bioanalysis; 2009 Jun; 1(3):611-7. PubMed ID: 21083156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine.
    Dere R; Yi JH; Lei C; Saad OM; Huang C; Li Y; Baudys J; Kaur S
    Bioanalysis; 2013 May; 5(9):1025-40. PubMed ID: 23641694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics.
    Kaur S; Xu K; Saad OM; Dere RC; Carrasco-Triguero M
    Bioanalysis; 2013 Jan; 5(2):201-26. PubMed ID: 23330562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
    Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
    Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biotherapeutic bioanalysis: a multi-indication case study review.
    Myler HA; Given A; Kolz K; Mora JR; Hristopoulos G
    Bioanalysis; 2011 Mar; 3(6):623-43. PubMed ID: 21417732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality.
    Hock MB; Thudium KE; Carrasco-Triguero M; Schwabe NF
    AAPS J; 2015 Jan; 17(1):35-43. PubMed ID: 25380723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
    Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
    Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physical and Chemical Stability of Antibody Drug Conjugates: Current Status.
    Ross PL; Wolfe JL
    J Pharm Sci; 2016 Feb; 105(2):391-397. PubMed ID: 26869406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analytical methods for physicochemical characterization of antibody drug conjugates.
    Wakankar A; Chen Y; Gokarn Y; Jacobson FS
    MAbs; 2011; 3(2):161-72. PubMed ID: 21441786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical considerations for the pharmacokinetic and immunogenic assessment of antibody-drug conjugates.
    Sauerborn M; van Dongen W
    BioDrugs; 2014 Aug; 28(4):383-91. PubMed ID: 24842227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bioanalysis in the development of antibody-drug conjugates].
    Li XL; Chen XY; Zhong DF
    Yao Xue Xue Bao; 2016 Apr; 51(4):517-28. PubMed ID: 29859519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-drug conjugate bioanalysis using LB-LC-MS/MS hybrid assays: strategies, methodology and correlation to ligand-binding assays.
    Wang J; Gu H; Liu A; Kozhich A; Rangan V; Myler H; Luo L; Wong R; Sun H; Wang B; Vezina HE; Deshpande S; Zhang Y; Yang Z; Olah TV; Aubry AF; Arnold ME; Pillutla R; DeSilva B
    Bioanalysis; 2016 Jul; 8(13):1383-401. PubMed ID: 27277879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linker technologies for antibody-drug conjugates.
    Nolting B
    Methods Mol Biol; 2013; 1045():71-100. PubMed ID: 23913142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of intact antibody-drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography-mass spectrometry.
    Xu K; Liu L; Saad OM; Baudys J; Williams L; Leipold D; Shen B; Raab H; Junutula JR; Kim A; Kaur S
    Anal Biochem; 2011 May; 412(1):56-66. PubMed ID: 21216214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of an immunoassay to selectively quantify the naked antibody of a new Antibody Drug Conjugate--SAR566658--for pharmacokinetic interpretation improvement.
    Pascual MH; Verdier P; Malette P; Mnich J; Ozoux ML
    J Immunol Methods; 2013 Oct; 396(1-2):140-6. PubMed ID: 23892158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.